Compare Merck Tbk. (MERK) vs Mizuho Leasing Indonesia Tbk. (VRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck Tbk. vs Mizuho Leasing Indonesia Tbk. — how do they compare? Merck Tbk. trades at Rp3,840 (market cap 1.7T, 37.6K 24h volume), while Mizuho Leasing Indonesia Tbk. trades at Rp74 (market cap 426.55B, 817.9K 24h volume). The key difference: Merck Tbk. is far larger — about 4× Mizuho Leasing Indonesia Tbk.'s market cap, and Mizuho Leasing Indonesia Tbk. is more actively traded (817.9K versus 37.6K). Which is the better fit depends on your goals.
| MERK | VRNA | |
|---|---|---|
Market Cap | 1.7T | 426.55B |
Volume | 37.6K | 817.9K |
Lot | 376 | 8.18K |
Turnover | 144.47M | 61.22M |
Average Price | 3,842.23 | 74.86 |
Value | 144.47M | 61.22M |
Indicative Equilibrium Price | 3,840 | — |
Indicative Equilibrium Volume | 7 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck Tbk.
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →About Mizuho Leasing Indonesia Tbk.
PT Verena Oto Finance (the Company) was established under its original name of PT Maxima Perdana Finance base on notarial deed No.43 of Mrs Sri Nanning, S.H, dated on Jul 21, 1993. The Companys articles of association has been amended several times, most recently by notarial deed No. 32 of Fathiah Helmi, S.H., dated Mar 26, 2007, concerning among others, the change in the Companys name, increase authorized, change in par value, and increase paid-up capital.
Read more on VRNA →
